The combination of neutrophil-to-lymphocyte ratio and serum carbohydrate antigen 19-9 level as a prognostic indicator in patients with recurrent pancreatic cancer

Teruhisa Sakamoto, Hiroaki Saito, Ei Uchinaka, Masaki Morimoto, Masataka Amisaki, Naruo Tokuyasu, Soichiro Honjo, Keigo Ashida, Yoshiyuki Fujiwara

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background/Aim: We retrospectively investigated the relationship between prognosis and combined neutrophil-to-lymphocyte ratio (NLR) and serum carbohydrate antigen 19-9 (CA19-9) levels in patients with recurrent pancreatic cancer. Patients and Methods: We enrolled 66 patients whose pancreatic cancer recurred. Results: Based on ROC analysis results, the patients were divided into NLRHigh (NLR ≥1.69) or NLRLow (NLR <1.69), and into CA19-9High (CA19-9 ≥107.95 U/ml) or CA19-9Low (CA19-9 <107.95 U/ml). When the patients were grouped by combined NLR and CA19-9, their 2-year survival rates were NLRLow/CA19-9Low: 58.7%; NLRLow/CA19-9High or NLRHigh/CA19-9Low (grouped together): 11.2%; and NLRHigh/CA19-9High: 0% (p<0.0001). Finally, in multivariate analysis, the combination of NLR and serum CA19-9 level was an independent prognostic factor in patients with recurrent pancreatic cancer. Conclusion: The combination of NLR and serum CA19-9 level is a useful prognostic indicator for recurrent pancreatic cancer.

Original languageEnglish
Pages (from-to)5497-5503
Number of pages7
JournalAnticancer research
Volume38
Issue number9
DOIs
Publication statusPublished - 09-2018
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'The combination of neutrophil-to-lymphocyte ratio and serum carbohydrate antigen 19-9 level as a prognostic indicator in patients with recurrent pancreatic cancer'. Together they form a unique fingerprint.

  • Cite this